Drug intelligence / Profile preview

IDC332

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IDC332 is a novel monoclonal antibody currently in the lead identification stage of preclinical development by Prestige Biopharma. It is being developed for the treatment of various solid tumors. As a "Novel Concept Antibody," it represents a part of Prestige Biopharma's innovative drug pipeline, though its specific biological target and detailed mechanism of action have not yet been publicly disclosed.

Beyond the preview

Go deeper on IDC332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC332.

Explore the full profile